Patients with hypertension (H) with metabolic syndrome (MS) have a high risk of cardiovascular events. The aim of the study was to assess the effects of combination therapy with Telmisartan (T) and Amlodipine (A) on BP, left ventricular (LV) hypertrophy, LV diastolic function in patients with hypertension and MS.Design and Method:
Sixty four patients with second and third stage hypertension and metabolic syndrome were provided to T (20 mg) + A (5 mg) in combination once a day (29 males and 35 females). The presence of metabolic syndrome was diagnosed by “Harmonized” Metabolic Syndrome definition. Anthropometric measures and echocardiography was performed at baseline and after 24 weeks of therapy. Statistical comparisons were performed by 2 tailed Student's t test for quantitative parameters.Results:
All patients completed the study without showing intolerance or side effects to the drugs. At the end of the study therapy normalized BP (125.6 ± 4.8/75.2 ± 2.3 mmHg vs. 172,63 ± 6.8/105.9 ± 5.2 mmHg, p < 0.05) in 95.3% of patients. LV mass index reduced from 159.2 ± 6.4 to 133.6 ± 3.7 g/m2, (p < 0.05) in 79.7 % of patients. At the end of the study E/A ratio increased from 0.89 ± 0.02 to 1.38 ± 0.03 (p < 0.002) in 84.4 % of patients. IVRT has been decreased from 105.1 ± 6.4 to 75.5 ± 4.2 msec (p < 0.05) in 82.8% of patients. Deceleration time passed from 171.4 ± 8. to 130.2 ± 2.8 msec (p < 0.01) in 86.0% of patients.Conclusions:
These data suggest significant antihypertensive efficacy of the combination of T 20 mg + A 5 mg. Combination therapy with T + A has been demonstrated qualitative regression of LV hypertrophy and improvement of LV diastolic function in patients with second and third stage hypertension and metabolic syndrome.